A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anaemia in Chronic Kidney Disease Patients Not on Dialysis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Adverse reactions; Registrational
- Sponsors AstraZeneca
- 03 Apr 2018 Planned End Date changed from 30 Mar 2018 to 25 Sep 2018.
- 03 Apr 2018 Planned primary completion date changed from 30 Mar 2018 to 25 Sep 2018.
- 20 Jul 2017 Planned End Date changed from 31 Mar 2018 to 30 Mar 2018.